Recruiting
Phase 2

Zanubrutinib & Lisocabtagene Maraleucel

Sponsor:

Aseel Alsouqi

Code:

NCT05873712

Conditions

Recurrent Transformed Chronic Lymphocytic Leukemia

Refractory Transformed Chronic Lymphocytic Leukemia

Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma

Recurrent Transformed B-Cell Non-Hodgkin Lymphoma

Recurrent Transformed Non-Hodgkin Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Marrow Biopsy

Computed Tomography

Cyclophosphamide

Fludarabine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-29. This information was provided to ClinicalTrials.gov by Aseel Alsouqi on 2025-11-24.